An interventional study of Pulmunary veins reconnection plus hidden slow conduction ablation and Pulmunary veins (PV) reconnection ablation only in Atrial Fibrillation, sponsored by Centro Medico Teknon. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-12-12.
Sponsored by Centro Medico Teknon · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Over recent years, pulmonary vein isolation (PVI) procedures have demonstrated progressively enhanced efficacy and safety, resulting in a substantial increase in the number of atrial fibrillation ablations, not only as a first-line treatment but also for repeat procedures. However, there is still a notable lack of randomized evidence in this area, which limits guidance and decision-making in clinical practice. Recently, the investigators found that employing short-coupled atrial extrastimuli revealed highly fragmented or double atrial evoked electrograms (EGMs) in AF patients, termed as hidden slow conduction (HSC). Identifying HSC sites may provide insight into the early identification of the arrhythmogenic substrate, offering a potential target for ablation This multi-center, prospective, randomized, controlled trial will include two arms: one investigational (PV reconnection + HSC) and one control (PV reconnection). All the subjects will be followed for 12 months after the ablation procedure.
The aim of our study is to investigate the impact of ablating HSC sites on arrhythmia recurrence in repeat ablation procedures. The hypothesis is that the additional ablation of HSC zones may improve the freedom from atrial arrhythmia recurrence after repeat ablation procedure.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
This study's planned enrollment of 212 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Centro Medico Teknon is the lead sponsor of 20 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoning pulmunary veins (PV) reconnection checking and ablation plus identification and ablation of hidden sites of slow conduction (HSC)
Procedure: Pulmunary veins reconnection plus hidden slow conduction ablation
Patients undergoning PV reconnection checking and ablation only.
Procedure: Pulmunary veins (PV) reconnection ablation only
Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium. HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm. After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed. The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms).
Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
Atrial arrhythmias recurrence
The primary endpoint of the study aims to establish the impact of targeting HSC sites alongside PV gaps in repeat ablation procedures for patients with recurrent AF. Specifically evaluating the freedom from atrial tachyarrhythmia recurrence (documented AF/AT/AFL lasting at least 30s).
Time frame: up to 12 moths
Burden of atrial arrhythmias
Arrhythmic burden (average percentage of time in AF/AT in 24h Holter)
Time frame: up to 12 moths
incidence of periprocedural complications (pericardial effusion)
incidence of periprocedural complications such as pericardial effusion
Time frame: up to 12 months
Use of antiarrhythmic drugs
Use of antiarrhythmic drugs after the blanking period of 60 days.
Time frame: up to 12 months
incidence of periprocedural complications (peripheral complication)
incidence of periprocedural complications such as peripheral complication
Time frame: up to 12 moths
incidence of periprocedural complications (transient ischemic attack or stroke)
incidence of periprocedural complications such as transient ischemic attack or stroke
Time frame: up to 12 months
Concentration of intramyocardial fat (inFAT) into the HSC points
Concentration of intramyocardial fat (inFAT) into the atrial area where we found the HSC points
Time frame: up to 12 months
Procedure features
procedure time
Time frame: up to 12 months
Atrial arrhythmias first recurrence
Evaluation of the atrial arrhythmias recurrence in patients with isolated PVs underwent HSC sites ablation
Time frame: up to 12 months
Left atrial wall thickness (LAWT) measurement into the HSC points
Left atrial wall thickness (LAWT) measurement into the atrial areas where we found the HSC points
Time frame: up to 12 months
procedure features
fluoroscopy time
Time frame: up to 12 months
procedure features
fluoroscopy dose
Time frame: up to 12 months
procedure features
number of radiofrequency (RF) applications
Time frame: up to 12 months
procedure times
radiofrequency (RF) total delivery time
Time frame: up to 12 months
No study locations are listed for this record.
Start is estimated for Dec 2024; primary completion for Sep 2026, 21 months later.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 21 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro Medico Teknon